HTA

On April 1, 2026, the submission period for Joint Scientific Consultations (JSCs) requests under the EU Health Technology Assessment Regulation (HTAR) framework opened. JSCs offer health technology developers the opportunity to seek scientific advice on the information and evidence required for a potential future Joint Clinical Assessment. Requests related to both medical devices and medicines can be submitted until April 29, 2026.

In April 2026, the Canary Islands Healthcare Evaluation Service is working on several HTAs, including evaluations in e-health, IVD, neuromodulation, obstetrics and gynecology, and some other fields.

On March 20, 2026, the Danish Healthcare Quality Institute (DHQI) opened a call for submissions of clinical issues for health technology assessment (analysis or evaluation). Proposals from healthcare stakeholders will undergo validation and prioritization, with selected topics taken forward for evaluation and the development of national recommendations.

In late March 2026, Norway’s “New Methods” framework announced a revised process for managing medical technologies (i.e., medical devices, in-vitro diagnostics, procedures), effective May 1, 2026. The update introduces new entry pathways, application process, prioritization criteria, and procedural changes such as early assessment and implementation meetings. Medical device companies are invited to a digital information session on April 17, 2026, with registration required by April 14, 2026.

In January 2026, the Belgian Health Care Knowledge Centre (KCE) published one Health Technology Assessment report on blood-based biomarkers in mild traumatic brain injury and two Health Service Research (HSR) reports addressing chronic pain management and the shift from inpatient to day and ambulatory care.

On January 07, 2026, the submission period for Joint Scientific Consultations (JSCs) requests under the EU Health Technology Assessment Regulation (HTAR) framework opened. JSCs offer health technology developers the opportunity to seek scientific advice on the information and evidence required for a potential future Joint Clinical Assessment. Requests related to both medical devices and medicines can be submitted until February 04, 2026.

In December 2025, the National Institute for Health and Care Excellence (NICE) in England updated its manual on technology appraisal and highly specialised technologies. The scope and terminology were clarified, and further details were provided to support the production of technology appraisal and highly specialised technologies on HealthTech (that is, medical devices, diagnostics, digital technologies).

On October 17, 2025, the European Commission adopted an implementing regulation that sets detailed procedural rules for Joint Clinical Assessments of medical devices and in vitro diagnostics under the HTA Regulation, which entered into force on 12 January 2025.

On October 6, 2025, the European Digital Health Technology Assessment (EDiHTA) framework announced the publication of its first scientific paper on stakeholder perspectives in digital health assessment. Furthermore, digital health innovators are invited to complete a short survey to inform development of the EDiHTA toolkit.

As of October 2025, the Swedish Dental and Pharmaceutical Benefits Agency is working on health technology assessments in several areas, including endocrine, e-health, and neurology procedures.

As of September 2025, the Swedish Agency for Health Technology Assessment and Assessment of Social Services is working on health technology assessments in several areas, including in-vitro diagnostics, e-health, and gynecology procedures.

In August 2025, the National Institute for Health and Care Excellence (NICE) announced two new projects within its Health Technology Assessment Innovation Laboratory (HTA Lab). The projects explore generative AI technologies in economic modelling and how AI can support and enhance NICE’s HTA processes through automation, predictive modeling, and reasoning systems.